Pluri (FRA:4DX) Moat Score: 3/10 (As of Jul. 02, 2026)


FRA:4DX Pluri Inc FRA:4DX
25 GF Score
Price €5.60
GF Value €17.39
! 6 Warning Signs
View Full Analysis

What is Pluri Moat Score?

Pluri FRA:4DX 25 Moat Score is 3 as of Jul. 02, 2026. GuruFocus rates FRA:4DX with a GF Score™ of 25/100 and a GF Value™ of €17.39. The stock has 6 warning signs investors should review. Among 1,400 Biotechnology companies, Pluri ranks better than 75.5% on this metric.

Pluri has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Pluri has No Moat: Pluri Inc lacks significant market leadership and customer switching costs. The company does not possess strong brand strength or durable cost advantages. Its intellectual property and innovation capabilities are not sufficient to establish a competitive edge. Overall, the company has very weak or transient advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Pluri might have No Moat - Very weak/transient advantages.

Pluri  (FRA:4DX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Pluri Moat Score Related Terms

FRA:4DX vs MRKR, VYNE, LGVN: Moat Score Comparison

For the Biotechnology subindustry, Pluri's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pluri Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pluri's Moat Score distribution charts can be found below:

* The bar in red indicates where Pluri's Moat Score falls into.


FRA:4DX
25GF Score
Pluri Inc FRA:4DX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Pluri (FRA:4DX) has a Moat Score of 3 as of Jul. 02, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Pluri ranks #343 out of 1400 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Pluri's Moat Score too high?
Pluri's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Pluri's value of 3 is 50% above this industry median. Based on the distribution chart, Pluri ranks #343 out of 1400 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pluri has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Pluri's Moat Score compare to MRKR and VYNE?
According to the Biotechnology industry distribution chart, Pluri ranks #343 out of 1400 companies for Moat Score. This places Pluri in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Pluri's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pluri's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pluri's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pluri stock overvalued right now?
Pluri (FRA:4DX) has a current Moat Score of 3. The stock's GF Value™ is €17.39, compared to a current price of €5.60 — trading 67.8% below its estimated fair value. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Pluri's overall GF Score™ is 25/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Pluri (FRA:4DX), the current Moat Score is 3 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pluri (FRA:4DX) Overvalued in 2026?

Based on GuruFocus' analysis, Pluri stock appears to be undervalued. The current stock price of €5.60 is trading 67.8% below its estimated GF Value™ of €17.39.

Key valuation signals for FRA:4DX:

  • Moat Score: 3
  • GF Value™: €17.39 vs. price of €5.60 (67.8% below fair value)
  • GF Score™: 25/100 with 6 warning signs
  • Industry Position: 50% above the Biotechnology median (#343 of 1400)

No single metric tells the full story. See the FRA:4DX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pluri Business Description

Other Exchanges PLUR:USAPLUR:Israel
Address MATAM Advanced Technology Park, Building No. 5, Haifa, ISR, 3508409
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
25GF Score

Get the complete analysis for FRA:4DX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.60
Price
€17.39
GF Value